



Press Announcement

FOR IMMEDIATE RELEASE

Paladin Labs Inc. announces TPP approval for Antizol® - the only approved product for the treatment of ethylene glycol poisoning -

Montreal, PQ – December 1, 2000 – Paladin Labs Inc. (“Paladin”) (TSE: PLB) today announced that the Therapeutic Products Programme (“TPP”) granted Antizol® a Notice of Compliance permitting the sale of Antizol® in Canada.

In June 1999, Paladin acquired the exclusive Canadian distribution rights for Antizol® from Orphan Medical, Inc (NASDAQ:ORPH). Antizol® is the only product for the treatment of ethylene glycol intoxication approved by the U.S. Food & Drug Administration & TPP.

Dr. Nazira Amra, Product Manager for Antizol® stated, “While ethylene glycol poisoning is rare, when it does occur it can be fatal. Nowhere was this more apparent than the recent outbreak in Newfoundland which claimed the lives of two youths. Stocking of Antizol® in hospital emergency rooms is not only prudent but necessary. The approval of Antizol® in Canada has been long awaited by Canadian clinical toxicologists and marks an important advance in the treatment of this potentially fatal poisoning. According to clinical data published in the New England Journal of Medicine (March 18, 1999) Antizol®, administered early in the course of intoxication, prevents renal injury by inhibiting the formation of toxic metabolites.”

Jonathan Goodman, President & CEO of Paladin stated, “Based upon its improved pharmacokinetic profile over existing therapies, we are confident that Antizol® will rapidly become the standard of care for ethylene glycol intoxication. We are privileged to be associated with Orphan Medical and its goal to develop products dedicated to patients with inadequately treated or uncommon diseases. Paladin intends to launch Antizol® in the 1st Quarter of 2001.”

About Paladin Labs Inc.

Paladin Labs, headquartered in Montreal, Quebec is a Canadian developer, marketer and distributor of innovative pharmaceuticals currently offering products in urology, dermatology, rheumatology and other specialty markets. For more information about Paladin, please visit the Paladin Web Site at www.paladin-labs.com or send e-mail to info@paladin-labs.com.

Paladin Labs Inc. is a public company whose shares trade on the Toronto Stock Exchange under the symbol *PLB*.

About Orphan Medical, Inc.

Orphan Medical acquires, develops, and markets pharmaceuticals of high medical value for inadequately treated and uncommon diseases. The Company serves three strategic therapeutic market segments that are characterized by well-defined patient populations and served by physician specialists: oncology support, antidotes and sleep disorders. Orphan Medical's Internet Web site address is www.orphan.com.

Orphan Medical stock is traded on the NASDAQ National Market under the symbol *ORPH*.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements or predictions. These statements represent our judgement as of this date and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. Potential risks and uncertainties include, without limitation, those associated with product development, clinical trials, future revenues and profitability, and obtaining marketing approval.

For further information please contact:**Paladin Labs Inc.**

Lennie Ryer, C.A., CFE

Chief Financial Officer

Tel: 514-340-5067

e-mail: lryer@paladin-labs.com

The Equicom Group

Joanna Longo

Account Manager

Tel: 416-815-0700 ext.233

e-mail: jlongo@equicomgroup.com

Web Site: www.equicomgroup.com